BENCHMRK-1 & -2 Combined Efficacy % of Patients With HIV RNA <50 copies/mL at Week 24 by Tipranavir (TPV) Use in OBT (Complete Week 24 Data) No TPV in
{"Image DocumentName": "BENCHMRK-1 & -2 Combined Efficacy % of Patients With HIV RNA <50 copies/mL at Week 24\u2020 by Tipranavir (TPV) Use in OBT (Complete Week 24 Data)", "Image ImageDescription": "Subgroup. N. 66% No TPV in OBT. 36% TPV in OBT (HIV-1 sensitive to TPV by genotype) 70% 29% TPV in OBT (HIV-1 resistant to TPV by genotype) 46% More than 100 pts were treated with a TPV-containing regimen and in those patients with active TPV the response rate was the same that those patients with 2 active drugs. Once again seems that PK changes in RAL have no effect in efficacy. 25% Raltegravir + OBT. Placebo + OBT. Kumar, P. et al, EACS 2007, Poster P7.2/06. \u2020Virological failures carried forward.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}